Abstract 1777P
Background
Effective therapy in pediatric-type sarcomas for adult patients remains an unmet need, with older age being a poor prognostic factor. NGS can identify potential therapeutic targets and characterize the tumor microenvironment (TME) in these patients.
Methods
Whole-exome and whole-transcriptome NGS were performed on samples from 16 patients aged 4–62 years with pediatric-type fusion-driven sarcoma (PTFDS: Ewing sarcoma - EwS, alveolar rhabdomyosarcoma - AlvR) to identify potentially targetable molecular events and classify samples into TME subtypes. The frequency of targetable events was compared between younger and older patients; the selected cutoff of 30 years is a common age limit in disease-specific clinical trials.
Results
Detected genetic events included EWSR1-FLI1 (n = 9), PAX3-FOXO1 (n = 5), and EWSR1-ETV4 (n = 1) fusions; RB1 (n = 1) and PTEN (n = 1) losses; somatic and germline CDKN2A (n = 2) mutations, somatic TP53 (n = 2), PIK3CA (n = 1), ATM (n = 1) and germline BRCA1 (n = 1) mutations; FGFR4 (n = 2), MYC (n = 1), and EZH2 (n = 1) amplifications. We hypothesized that worse outcomes in older PTFDS patients could be associated with increased frequency of additional targetable driver events. We compared the frequency of targetable genetic events between younger (4-28 years, median = 23) and older (32-62 years, median = 40) patients with EwS and AlvR. Targetable events were more common in older (71%, 5/7) compared to younger patients (22%, 2/9), albeit the sample size was too small to reach statistical significance. Transcriptomic-based TME profiling showed that 94% (n =15) of patients had Fibrotic/Immune Desert subtypes associated with a predicted poor response to immune checkpoint inhibitors (ICI). One EwS patient had an Immune-Enriched subtype associated with predicted benefit from ICI. The distribution of TME subtypes within sarcoma types conforms well with previously reported lack of response to ICI in PTFDS patients.
Conclusions
Comprehensive molecular profiling revealed targetable events that may benefit older patients with PTFDS by expanding potential therapeutic options and inclusion in biomarker-driven trials without strict age limits.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
BostonGene, Corp.
Disclosure
A.P. Conley: Financial Interests, Personal, Research Funding: Eli Lilly, EpicentRx, Kronos Bio, Krystal Biotech, Inhbrx, NCI, Roche; Financial Interests, Personal, Research Grant: Chordoma Foundation; Financial Interests, Personal, Speaker, Consultant, Advisor: Aadi Biosciences, Guide Point. A. Aukhadieva, I. Zhuk, M. Voropaeva: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Novokreshchenova: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp. A.E. Shevkoplias: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. K. Zirov: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Makarova: Financial Interests, Personal, Financially compensated role: BostonGene, Corp. A. Dubrovskaya: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Nadiryan: Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Financially compensated role, employee: BostonGene, Corp. L. Balabanian: Financial Interests, Personal, Financially compensated role, employee: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp. A. Bagaev: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp.; Financial Interests, Personal, Proprietary Information: BostonGene, Corp. E. Choy: Financial Interests, Personal, Advisory Board: Sonata Therapeutics, Adaptimmune; Financial Interests, Personal, Research Funding: Adaptimmune, Amgen, AstraZeneca, Bayer, Exelixis, GSK, Iterion, Novartis, Merck, Mirati. R. Ratan: Financial Interests, Personal, Advisory Board: SpringWorks, Ipsen; Financial Interests, Personal, Advisory Role: Inhibrx; Financial Interests, Personal, Coordinating PI: Ayala, C4 Therapeutics, SpringWorks; Financial Interests, Personal, Research Funding: SpringWorks, C4 Therapeutics, Ayala; Financial Interests, Personal, Speaker, Consultant, Advisor, Invited Speaker: SpringWorks. L. Bednyagin: Financial Interests, Personal, Financially compensated role: BostonGene, Corp.; Financial Interests, Personal, Full or part-time Employment: BostonGene, Corp.; Financial Interests, Personal, Stocks/Shares: BostonGene, Corp. S.P. Chawla: Financial Interests, Personal, Stocks/Shares, Own stocks.: Cellestia pharma; Financial Interests, Personal, Stocks/Shares, Stocks: Adi Biopharma; Financial Interests, Personal, Ownership Interest, Owner and stocks: Counterpoint; Financial Interests, Institutional, Local PI, Clinical research: Amgen; Financial Interests, Institutional, Local PI, Research: Adi bio, NK Gene, BMS, Rain Therapeutic, Shasqui, Monopar, Ayala, Boeinger; Financial Interests, Personal, Local PI, Research: Rain Therapeutic, Molleculin.
Resources from the same session
1372P - Advanced non-small cell lung carcinoma in the era of immunotherapy: Survival and the risk of multiple primary malignancies
Presenter: Nahla Ali
Session: Poster session 06
1373P - Measuring PFS in clinical trials and observational studies of patients with NSCLC: A scoping review
Presenter: Marjon Verschueren
Session: Poster session 06
1374P - Analysis of evolution of patient reported side effects during treatment for advanced NSCLC
Presenter: Helena Linardou
Session: Poster session 06
1375P - Sequential ctDNA profiling in patients with advanced non-small cell lung cancer: An interim analysis of the COPE randomized study
Presenter: Antoine Italiano
Session: Poster session 06
Resources:
Abstract
1376P - Early detection of disease progression in NSCLC patients undergoing immunotherapy through ctDNA analysis
Presenter: Virginia Calvo de Juan
Session: Poster session 06
1377P - Association of anatomic proximity of brain parenchymal metastasis to the CSF space and upfront stereotactic radiosurgery to subsequent leptomeningeal metastasis development in brain metastatic NSCLC
Presenter: Shoaib Bashir
Session: Poster session 06
Resources:
Abstract
1378P - Improvements in stage IV non-small cell lung cancer survival differ by race in the US
Presenter: Oluwaseun Ayoade
Session: Poster session 06
1379P - c-Met protein overexpression and telisotuzumab vedotin efficacy by biopsy age, type, and region in the LUMINOSITY phase II study
Presenter: Jair Bar
Session: Poster session 06
1380P - PK/PD analysis of pembrolizumab, nivolumab and atezolizumab in NSCLC patients: The PIONeeR trial
Presenter: Joseph Ciccolini
Session: Poster session 06
1381P - Comparison between standard dose 75mg/m<sup>2</sup> and fixed dose at 50mg of cisplatin in the treatment of non-small cell lung cancer patients in term of response rate and toxicity profile
Presenter: Maher Salamoon
Session: Poster session 06